Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
Panelist discusses how HER2-directed tumor-agnostic therapies represent an emerging treatment paradigm focused on targeting HER2 mutations regardless of cancer type. Current agents such as trastuzumab deruxtecan show promise across multiple tumor types that express HER2, moving beyond traditional cancer-specific approaches. This precision medicine strategy may expand treatment options and improve outcomes for patients with HER2-altered cancers who previously had limited therapeutic choices.
Video content above is prompted by the following:
- Briefly review the current landscape of HER2-directed tumor-agnostic therapies. What are potential benefits of tumor-agnostic approaches in improving patient outcomes?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
